

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services
Disabled and Elderly Health Programs Group

March 1, 2023

Dana Flannery
Assistant Director
801 E. Jefferson, MD #4200
Phoenix, AZ 85034

Dear Dana Flannery:

The CMS Division of Pharmacy team has reviewed Arizona's State Plan Amendment (SPA) 22-0030 received in the CMS Division of Program Operations on December 12, 2022. This SPA describes the States Drug Utilization Review program.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that AZ-22-0030 is approved with an effective date of October 1, 2022. Our review was limited to the materials necessary to evaluate the SPA under applicable federal laws and regulations.

If you have any questions regarding this request, please contact Lisa Shochet at 410-786-5445 or Lisa.Shochet@cms.hhs.gov.

Sincerely,

Cynthia R.
Denemark -S

Digitally signed by
Cynthia R. Denemark -S
Date: 2023.03.01
15:12:19 -05'00'

Cynthia Denemark, R.Ph.
Acting Director
Division of Pharmacy
DEHPG/CMCS/CMS

cc: Suzanne Berman, Arizona Health Care Cost Containment System
Ruben Soliz, Arizona Health Care Cost Containment System
Brian Zolyns, Centers for Medicare & Medicaid Services (CMS) San Francisco
Whitney Swears, CMS, Division of Pharmacy

**TRANSMITTAL AND NOTICE OF APPROVAL OF
STATE PLAN MATERIAL
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES**

1. TRANSMITTAL NUMBER <u>22- 0030</u>	2. STATE <u>AZ</u>
3. PROGRAM IDENTIFICATION: TITLE <u>XIX</u> OF THE SOCIAL SECURITY ACT	

TO: CENTER DIRECTOR
CENTERS FOR MEDICAID & CHIP SERVICES
DEPARTMENT OF HEALTH AND HUMAN SERVICES

4. PROPOSED EFFECTIVE DATE
October 1, 2022

5. FEDERAL STATUTE/REGULATION CITATION
Section 1927(g) of the Social Security Act

6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)
a. FFY 23 \$ 0
b. FFY: 24 \$ 0

7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT

Page 74, 74a, 74b, 74c

8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)

Page 74, 74a, 74b, 74c


9. SUBJECT OF AMENDMENT
Describes Arizona's Drug Utilization Review Program

10. GOVERNOR'S REVIEW (Check One)

GOVERNOR'S OFFICE REPORTED NO COMMENT OTHER, AS SPECIFIED:

COMMENTS OF GOVERNOR'S OFFICE ENCLOSED

NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

11. SIGNATURE OF STATE AGENCY OFFICIAL


12. TYPED NAME
Dana Flannery

13. TITLE
Assistant Director

14. DATE SUBMITTED:
December 12, 2022

15. RETURN TO
Dana Flannery
801 E. Jefferson, MD#4200
Phoenix, AZ 85034

FOR CMS USE ONLY

16. DATE RECEIVED December 12, 2022	17. DATE APPROVED March 1, 2023
--	------------------------------------

PLAN APPROVED - ONE COPY ATTACHED

18. EFFECTIVE DATE OF APPROVED MATERIAL
October 1, 2022

20. TYPED NAME OF APPROVING OFFICIAL
Cynthia Denmark

19. SIGNATURE OF APPROVING OFFICIAL
Cynthia R. Denmark -S
Digitally signed by Cynthia R. Denmark -S
Date: 2023.03.01 15:12:48 -05'00'

21. TITLE OF APPROVING OFFICIAL
Acting Director, Division of Pharmacy

22. REMARKS

State/Territory: ArizonaCitation**4.26 Drug Utilization Review Program**

- 1927(g)
42 CFR 456.700
- A.1 The Medicaid agency meets the requirements of Section 1927(g) of the Act for a drug use review (DUR) program for outpatient drug claims.
2. The DUR program assures that prescriptions for CMS covered outpatient drugs are:
- Clinically appropriate
 - Medically necessary
- 1927(g)(1)(A)
42 CFR 456.705(g)
456.709(b)
- B. The DUR program is designed to educate physicians and pharmacists to identify and reduce the frequency of patterns of fraud, abuse, gross overuse, inappropriate or medically unnecessary care among physicians, pharmacists, and patients or clinical parameters associated with specific drugs as listed below:
- Potential and actual adverse drug reactions
 - Clinical appropriateness
 - Overutilization and underutilization
 - Appropriate use of generic products
 - Therapeutic duplication
 - Drug disease contraindications
 - Drug-drug interactions
 - Incorrect drug dosage or duration of drug treatment
 - Drug-allergy interactions
 - Clinical abuse/misuse
- 1927(g)(1)(B)
42 CFR 456.703 (d)
and (f)
- C. The DUR program shall assess data use against predetermined standards whose source materials for their development are consistent with peer-reviewed medical literature which has been critically reviewed by unbiased independent experts and the following compendia:
- American Hospital Formulary Service Drug Information
 - Drug Facts and Comparisons
 - UpToDate
 - National Comprehensive Cancer Network Guidelines (NCCN)
 - Micromedex
 - MediSpan
 - FirstDataBank

State/Territory: ArizonaCitation**4.26 Drug Utilization Review Program (Cont'd)**

- 1927(g)(1)(D)
42 CFR 456.703(b)
42 CFR 483.60
- D. DUR is not required for drugs dispensed to Medicaid recipients located in skilled nursing facilities that are in compliance with drug regimen review procedures as set forth in 42 CFR 483.60. The State has never-the-less chosen to include nursing home drugs in:
___ Prospective DUR
___ Retrospective DUR
- 1927(g)(1)(D)
42 CFR 456.705(b)
- E.1. The DUR program includes prospective review of drug therapy at the point of sale before a prescription is filled or dispensed to a Medicaid recipient.
- 1927(g)(2)(A)(i)
42 CFR 456.705(b)
(1)-(7))
2. Prospective DUR includes processing each prescription submitted for adjudication through point-of-sale edits prior to filling the prescription and dispensing it to the Medicaid recipient. The point-of-sale edits include the following:
- Therapeutic duplication
- Drug-disease contraindications
- Drug-drug interactions
- Drug-interactions with non-prescription or over-the-counter drugs
- Incorrect drug dosage
- Incorrect duration of drug treatment
- Drug allergy interactions
- Clinical abuse/misuse/overuse
- 1927(g)(2)(A)(ii)
42 CFR 456.705(c)
and (d)
3. Prospective DUR includes counseling for Medicaid recipients based on regulations and standards established by the Arizona State Board of Pharmacy..
- 1927(g)(2)(B)
42 CFR 456.709(a)
- F.1. The DUR program includes retrospective DUR through its electronic drug claims processing system and information retrieved from the system and ongoing periodic examination of claims data and other records to identify:
- Patterns of fraud and abuse
- Gross overuse
- Inappropriate or medically unnecessary care among physicians, pharmacists, Medicaid recipients, or associated with specific drugs or groups of drugs.

State/Territory: ArizonaCitation**4.26 Drug Utilization Review Program (Cont'd)**1927(g)(2)(C)
42 CFR 456.709(b)

- F.2. The DUR program assesses data on drug use against explicit predetermined standards including but not limited to monitoring for:
- Therapeutic appropriateness
 - Overutilization and underutilization
 - Appropriate use of generic products
 - Therapeutic duplication
 - Drug-disease contraindications
 - Drug-drug interactions
 - Incorrect drug dosage/duration of drug treatment
 - Clinical abuse/misuse

1927(g)(2)(D)
42 CFR 456.711

3. The DUR program through its State DUR Board/Pharmacy & Therapeutics Committee, using data provided by the Board, provides for active and ongoing educational outreach programs to educate practitioners on common drug therapy problems to improve prescribing and dispensing practices.

1927(g)(3)(A)
42 CFR 456.716(a)

- G.1. The DUR program has established a State DUR Board either:
- Directly, or
- Under contract with a private organization

1927(g)(3)(B)
42 CFR 456.716
(A) AND (B)

2. The DUR Board membership includes health professionals (one-third licensed actively practicing pharmacists and one-third but no more than 51 percent licensed and actively practicing physicians) with knowledge and experience in one or more of the following:
- Clinically appropriate prescribing of covered outpatient drugs
 - Clinically appropriate dispensing and monitoring of covered outpatient drugs
 - Drug use review, evaluation and intervention

1927(g)(3)(C)
42 CFR 456.716(d)

3. The activities of the DUR Board may include:
- Retrospective DUR,
 - Application of Standards as defined in section 1927(g)(2)(C), and
 - Ongoing interventions for physicians and pharmacists targeted toward therapy problems or individuals identified in the course of retrospective DUR.

State/Territory: ArizonaCitation**4.26 Drug Utilization Review Program (Cont'd)**

1927(g)(3)(C)
42 CFR 456.711
(a)-(d)

- G.4 The interventions may include the following in appropriate instances:
- Information dissemination
 - Written, oral, or electronic reminders
 - Face-to-Face discussions
 - Intensified monitoring/review of prescribers/dispensers

1927(g)(3)(D)
42 CFR 456.712
(A) and (B)

- H. The State assures that the CMS Annual DUR Report shall be prepared and submitted to the Secretary, which incorporates a report for the State DUR Program, and that the State will adhere to the plans, steps, procedures as described in the report.

1927(h)(1)
42 CFR 456.722

- I.1. The State establishes, as its principal means for processing claims for covered outpatient drugs under this title, a point-of-sale electronic claims management system to perform on-line:
- real time eligibility verification
 - claims data capture
 - adjudication of claims
 - assistance to pharmacists, etc. applying for and receiving payment.

1927(g)(2)(A)(i)
42 CFR 456.705(b)

2. Prospective DUR is performed using an electronic on-line point of sale drug claims processing system.